Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio, Inc., a Cayman Islands–incorporated clinical‑stage biopharmaceutical company, files its Form 20‑F for the year ended December 31, 2025. The company is highly dependent on its lead oral candidate tinlarebant (LBS‑008) for autosomal recessive Stargardt disease and geographic atrophy. Top‑line Phase 3 DRAGON results were announced in December 2025, and Belite expects to submit an NDA to the FDA in the second quarter of 2026.
The report highlights extensive development, regulatory, manufacturing, competition and reimbursement risks typical for a single‑asset biotech with no approved products. Belite recorded net losses of approximately $31.6 million, $36.1 million and $77.6 million in 2023, 2024 and 2025, respectively, with an accumulated deficit of about $185.3 million as of December 31, 2025. Net cash used in operating activities was $29.8 million, $29.2 million and $40.7 million over the same periods, and the company expects operating expenses and cash burn to continue rising as clinical and potential commercialization efforts expand. As of December 31, 2025, Belite had 39,339,960 ordinary shares outstanding and U.S. net operating loss carryforwards at several subsidiaries, which may be subject to utilization limits.
BELITE BIO, INC Chief Medical Officer Hendrik Peter Scholl filed an initial ownership report showing indirect equity positions held through Bioptima Ltd. These include stock options over 100,000, 75,000 and 40,000 ordinary shares with exercise prices of 48.6800, 54.8800 and 158.3600, expiring between 2034 and 2036, plus 35,000 ordinary shares. Footnotes describe time-based vesting, with portions of these options vesting around September 1, 2025 and January 9 in 2027, 2028 and 2029, subject to continued service.
Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.
Belite Bio, Inc. director and Chief Financial Officer Chuang Hao-Yuan filed a Form 3 disclosing his existing equity holdings in the company. The filing lists several stock options to acquire ordinary shares, including options over 144,868 shares at an exercise price of $0.4386 per share expiring on December 22, 2030, and 26,112 shares at $6.00 per share expiring on April 17, 2032.
Additional options cover 120,834 ordinary shares at $14.45, 250,000 shares at $48.46, 200,000 shares at $54.88, 40,000 shares at $77.40, 80,000 shares at $93.02, and 150,000 shares at $158.36, each with expirations between 2033 and 2036. The filing also reports direct holdings of 100,000 American depositary shares and 195,264 ordinary shares, with each ADS representing one ordinary share.
BELITE BIO, INC director Chen Xiao-Hui has filed an initial ownership report showing a modest personal stake in the company. The Form 3 indicates beneficial ownership of 400 American depositary shares as of March 18, 2026. Each American depositary share represents one ordinary share of Belite Bio, giving the director economic exposure to 400 ordinary shares. This filing does not reflect a new purchase or sale, but simply records existing holdings as the director becomes subject to insider reporting rules.
BELITE BIO director John Michael Longo reported his initial beneficial ownership on a Form 3, showing two stock option awards over ordinary shares. One option allows him to buy 50,000 shares at $6.0000 per share, expiring on April 17, 2032, vesting monthly from April 28, 2022 over three years. A second option covers 60,000 shares at an exercise price of $58.8800, expiring on April 14, 2035, vesting in 36 equal monthly installments starting after April 15, 2025, subject to continued service.
BELITE BIO, INC director Lu Ita filed an initial Form 3 showing existing stock option holdings. The filing reports a stock option over 50,000 ordinary shares with a $14.45 exercise price, expiring on July 16, 2033. This option vests 22,500 shares on July 17, 2023, with the remaining 27,500 shares vesting in 22 equal monthly installments following June 28, 2023, subject to continued service.
The filing also reports a second stock option over 60,000 ordinary shares with a $58.88 exercise price, expiring on April 14, 2035. This option vests in 36 equal monthly installments for each full month of services completed following April 15, 2025, also subject to continued service. The document records holdings only and does not show any new purchases or sales.
Belite Bio director Gary Clark Biddle filed an initial ownership report showing stock option holdings in the company. He holds options covering 50,000 ordinary shares at an exercise price of $6.00 per share, expiring on April 17, 2032. This option vests over three years: 20,000 shares vest in 12 equal monthly installments after April 28, 2022, and the remaining 30,000 vest in 24 monthly installments after the first anniversary of that date, all subject to continued service. He also holds options over 60,000 ordinary shares at an exercise price of $58.88 per share, expiring on April 14, 2035, which vest in 36 equal monthly installments after April 15, 2025, subject to continued service. The filing lists these option positions and vesting terms rather than reporting any share purchases or sales.
Belite Bio, Inc. director and CEO Lin Yu-Hsin has reported initial equity holdings, including stock options and share positions. The filing lists multiple stock options over ordinary shares with exercise prices from $0.4386 to $158.3600, expiring between 2030 and 2036. Several options are already fully vested, while others vest monthly through August 2028 and in annual tranches on January 9, 2027, January 9, 2028, and January 9, 2029. Lin also holds American depositary shares and ordinary shares directly. This Form 3 records existing positions; it does not show new buying or selling activity.
Belite Bio director Chen Wan-Shan filed an initial ownership report showing direct holdings in the company. The filing lists 10,196 American depositary shares and 23,463 ordinary shares held directly. A footnote explains that each American depositary share represents one ordinary share of Belite Bio.